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Introduction: Intravascular large B-cell lymphoma is a rare aggressive disseminated disease characterized by the
presence of lymphoma cells in small vessels without lymphadenopathy. Rituximab, a novel monoclonal antibody
against the CD20 B-cell antigen, has been reported to be effective in treating intravascular large B-cell lymphoma.
However, adverse events have been reported in association with rituximab infusion.
Case presentation: We report the case of a 54-year-old Japanese man diagnosed with Asian variant intravascular
large B-cell lymphoma who died within five hours of the initiation of a first course of chemotherapy including
rituximab. Autopsy results suggested that the patient died of severe systemic inflammatory response syndrome.
A literature review revealed that rituximab administered during the second course of chemotherapy (instead of
during the first course) appears to reduce the incidence of infusion reactions (from 48% to 15%) without altering
the frequency of complete remission outcomes.
Conclusions: Our data indicate that the incidence of adverse reactions to rituximab can be markedly decreased if
the tumor load is first reduced with an initial course of chemotherapy excluding rituximab. Future prospective
studies of the timing of rituximab administration are warranted.
Keywords: Rituximab, CD20 antibody, Cytokine release syndrome, Systemic inflammatory response syndrome,
R-CHOP, Diffuse large-cell lymphomaIntroduction
Intravascular large B-cell lymphoma (IVLBCL) is a rare
type of extranodal large B-cell lymphoma characterized
by the proliferation of lymphoma cells within the lumina
of small blood vessels and capillaries [1]. There is cur-
rently no standard therapeutic strategy for IVLBCL.
Many cases of IVLBCL have been successfully treated
with a chemotherapy regimen comprising rituximab, cyclo-
phosphamide, doxorubicin, vincristine, and prednisone
(R-CHOP). Rituximab is a therapeutic monoclonal anti-
body against the CD20 B-cell antigen, and is reportedly ef-
fective in treating IVLBCL [2,3]. However, 84% to 95% of* Correspondence: katsuhiromakino@gmail.com
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reproduction in any medium, provided the orpatients who receive a rituximab-based regimen experi-
ence treatment-related adverse events; approximately 90%
of these are of mild to moderate severity, and most involve
flu-like symptoms (fever, chills, nausea, and asthenia) [4].
The general overall risk of serious adverse events after
rituximab administration is very low, but the compound
has been associated with severe and unpredictable compli-
cations, including cytokine release syndrome (CRS), sys-
temic inflammatory response syndrome (SIRS), and death
[5,6]. Similar side effects have been reported during the
treatment of other forms of cancer, such as acute lympho-
cytic leukemia and chronic lymphocytic leukemia [7,8].
The frequency of use of rituximab has been increasing as
it is now applied to a myriad of conditions, and adverse
events are more commonly reported [9].Ltd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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Asian variant IVLBCL who died from SIRS during the
first course of a chemotherapy regimen that included ri-
tuximab. We also present a review of the literature asso-
ciated with rituximab use among patients with IVLBCL.
To the best of our knowledge, this is the first such re-
view. We observed that a simple alteration in the timing
of rituximab infusion can markedly reduce the incidence
of adverse effects without affecting treatment efficacy.
Case presentation
A 54-year-old Japanese man with no relevant medical
history presented at our hospital complaining of con-
tinuous fever and malaise of one month’s duration. His
family history was unremarkable, and he had never
smoked and did not frequently consume alcohol. Blood
tests showed elevated levels of lactate dehydrogenase,
soluble IL-2 receptor, and ferritin, as well as bicytopenia.
A blood disorder, such as malignant lymphoma or hemo-
phagocytic syndrome, was thus suspected. A bone marrow
aspiration performed six days after admission revealed
hemophagocytic syndrome, but without any evidence of
malignancy. Accordingly, the patient underwent two ses-
sions of steroid pulse therapy comprising intravenous ad-
ministration of methylprednisolone sodium succinate
(1000mg/day for three days) initiated on post-admission
days 11 and 17. However, his general condition did not
improve, and laboratory analysis revealed that his lactate
dehydrogenase and soluble IL-2 receptor levels remained
elevated, which was strongly suggestive of IVLBCL. Ran-
dom skin biopsies of the abdominal wall, forearm, and
thigh were all negative for IVLBCL. These areas were
selected for ease of access. However, percutaneous liver
biopsy revealed sinusoidal infiltration of lymphoma cells
positive for CD20 and CD79a and negative for CD5. On
the basis of these findings, the patient was diagnosed with
Asian variant IVLBCL 22 days after admission.
The patient was treated with an R-CHOP-like chemo-
therapy regimen comprising rituximab (250mg/m2), cyclo-
phosphamide (500mg/m2), doxorubicin (33mg/m2), and
vincristine (0.9mg/m2) 24 days after admission. Prednisol-
one was not included because it had been administered
since the diagnosis of hemophagocytic syndrome, and had
been continuously administered during the 12 days before
chemotherapy initiation. It is generally accepted that fur-
ther prednisolone administration may have caused severe
immunosuppression. Furthermore, in IVLBCL, rituximab-
induced infusion reactions may occur more frequently
than in other diseases because many tumor cells are
lodged in blood vessels. We followed the guidelines of a
Japanese IVLBCL study group, which recommended
that all drug doses should be reduced by two-thirds to
avoid tumor lysis syndrome after the first course of R-
CHOP chemotherapy. The patient was administeredcyclophosphamide, doxorubicin, and vincristine immedi-
ately before rituximab infusion, which was given at a cal-
culated dose of 250mg/m2. Rituximab infusion was
initiated at a rate of 25mg/h for the first hour along with
acetaminophen and diphenhydramine. The infusion rate
was gradually increased to 100mg/h by the second hour,
at which point the patient complained of nausea. His
temperature gradually increased to 41.2°C, and he had a
rapid pulse of 126 beats/min. SIRS was diagnosed, and the
infusion was discontinued. Arterial blood gas revealed a
pH of 6.913 and high levels of lactic acid (16.0mmol/L;
normal range: 0.5 to 1.8mmol/L), indicating lactic acidosis.
Laboratory analysis revealed high levels of lactate de-
hydrogenase (2448IU/L; normal range 105 to 333IU/L),
aspartate aminotransferase (635IU/L; normal range 10 to
34IU/L), alanine aminotransferase (640IU/L; normal range
10 to 40IU/L), and potassium (8.3mEq/L; normal range
3.5 to 4.5mEq/L). Unfortunately, we could not measure
his serum IL-6 levels. Sustained ventricular tachycardia
occurred due to metabolic derangement half an hour later.
Hypotension became refractory to pressors, and the pa-
tient eventually died of asystole five hours after rituximab
infusion.
Autopsy revealed invasion of tumor cells into the liver,
lung, kidney, spleen, and pituitary gland. This case differs
from another autopsy case in which the patient died of
IVLBCL without undergoing chemotherapy. First, fewer
tumor cells were present. Second, the tumor cells were
too degenerated for immunohistochemical characteri-
zation (there was a loss of antigenicity). Finally, necrosis,
degenerative atrophies, and ischemic changes were found
in the cells and tissues of multiple organs. These findings
suggest that SIRS accompanied the destruction of tumor
cells by chemotherapy, which led to peripheral circulatory
failure and ischemia in multiple organs. There was no evi-
dence of active tumor lysis syndrome demonstrated by
lower uric acid levels. Thus, the death of the patient was
attributed to SIRS, which occurred subsequent to the
rapid rituximab-induced destruction of tumor cells and
the resulting cytokine release.Discussion
Intravascular large B-cell lymphoma is a rare variant of
CD20+ large B-cell lymphoma, which is often suspected
on the basis of clinical symptoms such as fever, night
sweats, and weight loss, as well as on the basis of labo-
ratory data such as elevated levels of serum lactate
dehydrogenase and soluble IL-2 receptor [2,3]. These
characteristic signs and symptoms have been postulated
to be due in part to blood flow disturbance and micro-
embolism as a result of the proliferation of lymphoma
cells within the lumina of the small blood vessels, which
leads to multiple organ damage [10].
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the B-cell marker CD20, and it has been shown to be ef-
fective in the treatment of IVLBCL [2,3]. The R-CHOP
regimen comprises rituximab, cyclophosphamide, doxo-
rubicin, vincristine, and prednisolone. The complete re-
sponse (CR) rate is reportedly higher for patients with
IVLBCL who have undergone chemotherapy with rituxi-
mab (R-chemotherapy group) compared with those who
have not (chemotherapy group): in one study, a CR was
achieved by 82% of patients in the R-chemotherapy group
and by 51% of those in the chemotherapy group.
The overall risk of serious adverse events associated
with the use of rituximab is very low. However, some pa-
tients have been reported to develop severe rituximab-
induced infusion reactions, including CRS, SIRS, and
death [5,6]. These noticeable adverse effects may be as-
sociated with a high tumor burden or advanced disease
progression. The pathophysiology of this reaction is at-
tributed to the release of cytokines, and usually occurs
after the first administration of rituximab [5,8]. Massive
cytokine release leads to the potentially severe condition
known as CRS. The mechanism of cytokine release has
been hypothesized to be related to the cross-linking of
rituximab to CD20+ cells, subsequent complement acti-
vation and lysis of these target cells, and, finally, the re-
lease of target cell cytokines (such as IFN-γ, IL-6, IL-8,
and TNF-α) within approximately two hours of the first
antibody infusion [5,8]. Furthermore, macrophage re-
cruitment contributes to the release of cytokines via in-
teractions between macrophage Fcγ receptors and the Fc
portion of the monoclonal antibody [11]. In addition, in
severe cases of rituximab-induced CRS, a 5- to 10-fold
increase in liver enzymes, elevation of D-dimer and lactate
dehydrogenase levels, and prolongation of prothrombin
time are commonly observed [12,13]. Cytokine release
from apoptotic CD20+ tumor cells is more severe in pa-
tients with a higher tumor burden in their peripheral
blood [12]. In such patients, CRS is prone to progress to
SIRS. A cutoff value for cytokine levels in circulation has
not been determined, and this phenomenon has been
poorly studied. A gradual increase in the rituximab injec-
tion rate (for example, starting at 25mg/h and titrating
higher at 25 to 50mg/h every 30min) may be useful for de-
tecting CRS in its incipient stages and preventing SIRS.
To identify published data on IVLBCL treatments, we
searched the Japan Medical Abstracts Society and PubMed
websites using ‘intravascular’ and ‘lymphoma’ as search
queries, and selected articles published between 1994 and
2011. The search was limited to IVLBCL patients. From
these published clinical studies and case reports, as well as
our own cases, we extracted cases in which rituximab had
been used and checked the time of rituximab administra-
tion, its efficacy, and the incidence of adverse events.
Using Fisher’s exact test, we evaluated the distribution ofvariables between the group that received rituximab dur-
ing the first course (1st R-group) of chemotherapy and the
group that received rituximab during the second or later
courses (2nd R-group). All probability values were two-
tailed and had an overall significance level >0.05.
The search of the literature published between 1994
and 2011 identified 56 clinical cases from 23 papers
reporting the use of rituximab in patients diagnosed with
IVLBCL. The data shown in Tables 1 and 2 indicate that
the distribution of patients between the group that re-
ceived rituximab during the first course and the group
that received the drug during the second or later courses
was equivalent [1,3,14-35]. The chemotherapy regimens
employed comprised CHOP or modified CHOP. Adverse
events related to rituximab infusion were observed in 18
(32%) of the 56 patients. Of these 18 patients, 14 (48%)
were among the 29 included in the 1st R-group, and four
(15%) were among the 27 included in the 2nd R-group.
Patients who received rituximab during the first course
of chemotherapy developed adverse events significantly
more often than those who received the drug later in the
treatment regimen (P=0.010). In the 1st R-group, five of
these 14 patients developed hypoxia in association with
the rituximab infusion, including Grade 3 severe hypoxia
in two. Grade 3 sick sinus syndrome was also observed.
All patients except for our present case recovered with-
out complications (Table 1).
Furthermore, the data shown in Tables 1 and 3 indi-
cate that a CR was achieved by 17 (85%) of 20 patients
in the 1st R-group and nine (90%) of 10 patients in the
2nd R-group. There was no significant difference be-
tween the groups in terms of the CR rate (P=1.000). Our
literature review suggests that treatment regimens intro-
ducing rituximab during the second or later courses of
chemotherapy are associated with lower risks of adverse
effects without affecting treatment efficacy.
Thus, initiating rituximab administration during the
second course of chemotherapy appears to reduce the
incidence of infusion reactions without changing the CR
rate. This is in agreement with a clinical study that re-
ported that post-CHOP administration of rituximab sig-
nificantly reduced the incidence of adverse reactions
compared with pre-CHOP administration [36]. The most
probable mechanism is the reduction of tumor cells dur-
ing the first course of chemotherapy via a regimen such as
CHOP. It is very important to prevent CRS in patients
with IVLBCL since IVBCL is associated with hemophago-
cytic syndrome and thus elevated cytokine levels. In pa-
tients with chronic lymphocytic leukemia, large amounts
of white blood cells (>50.0×103 cells/μL) are a risk factor
for rituximab-induced infusion reactions [12,13]. However,
there is no way to measure the amount of tumor cells
present in patients with IVLBCL, although it has been
reported that patients with splenomegaly or tumor cells
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Shimada et al. [3] 1st: 23 cases NA 10 of 23 cases
developed infusion
reactions; hypoxia
was observed in 3 of
the 10 cases and
Grade 3 severe
hypoxia in 1 case
Shimada et al. [3] 2nd: 25 cases NA 4 of 25 cases
developed infusion
reactions
Ohkubo et al. [23] 1st CR None
Imahashi et al. [15] 1st CR NA
Aoyama et al. [14] 1st NC Grade 3 sick sinus
syndrome
Kaku et al. [16] 1st CR None
Okachi et al. [24] 1st: 2 cases CR NA
Wakamatsu et al. [34] 1st CR NA
Shimizu et al. [27] 1st: 5 cases CR NA
Takahashi et al. [31] 1st CR NA
Tanikawa et al. [33] 1st NC NA
Sawa et al. [26] 1st CR NA
Watanabe et al. [35] 1st CR NA
Sakurai et al. [25] 1st CR NA
Takizawa et al. [32] 1st CR NA
Nakano et al. [22] 1st NC NA
Kotake et al. [21] 2nd CR NA
Shinoda et al. [28] 2nd CR NA
Shimada et al. [1] 2nd CR None
Ishizuka et al. [17] 2nd CR NA
Iwagami et al. [18] 2nd CR NA
Kashizaki et al. [19] 2nd CR Unspecified*
Kobayashi et al. [20] 2nd PR NA
Sakurai et al. [25] 2nd CR None
Suzuki et al. [29] 2nd CR NA
Tadokoro et al. [30] 2nd CR NA
Our other case 1st CR Grade 1 fever, chills,
hypoxia
Present case 1st NA Death
NA, not applicable; CR, complete response; NC, no change; PR, partial
response. *In this case, rituximab administration was attempted during the
first course, but an infusion reaction was observed and the rituximab injection
was discontinued. However, rituximab was administered according to protocol
during the second course.
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perience infusion reactions [12,13]. Considering these
reports, a simple change in the timing of rituximab infu-
sion appears to markedly reduce the incidence of ad-
verse effects without affecting treatment success rates.Certainly, however, these data are from a small number
of patients, and the suggestion needs to be verified by
prospective randomized controlled trials.
It has also been reported that patients who have not
undergone steroid therapy and/or chemotherapy before
receiving the first dose of rituximab show a tendency to
develop adverse events related to its infusion, more so
than those who have undergone these treatments before-
hand. We did not use steroids immediately before the
injection of rituximab in the present case, but it could
have been helpful in preventing an infusion reaction.Conclusions
This case report demonstrates that rituximab adminis-
tration during the first course of chemotherapy can be
extremely dangerous for IVLBCL patients. Our litera-
ture review indicates that the incidence of adverse reac-
tions can be markedly decreased if the tumor load is
first reduced with an initial course of rituximab-free
chemotherapy followed by second or later courses of a
rituximab-based regimen. However, these data have been
derived from a small number of patients, and future pro-
spective studies of the timing of rituximab administration
are warranted.Consent
Written informed consent was obtained from the patient’s
next of kin for publication of this case report and any
accompanying images. A copy of the written consent is
available for review by the Editor-in-Chief of this journal.
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